Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer

IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Digestive and Liver Disease Pub Date : 2025-01-01 DOI:10.1016/j.dld.2024.07.022
Romain Chautard , Morgane Caulet , Olivier Bouché , Christophe Borg , Sylvain Manfredi , Olivier Capitain , Jean-Philippe Spano , William Raoul , Maxime Guéguinou , Olivier Herault , Aurélie Ferru , Cédric Pobel , Olivier Sire , Thierry Lecomte
{"title":"Evaluation of serum mid-infrared spectroscopy as new prognostic marker for first-line bevacizumab-based chemotherapy in metastatic colorectal cancer","authors":"Romain Chautard ,&nbsp;Morgane Caulet ,&nbsp;Olivier Bouché ,&nbsp;Christophe Borg ,&nbsp;Sylvain Manfredi ,&nbsp;Olivier Capitain ,&nbsp;Jean-Philippe Spano ,&nbsp;William Raoul ,&nbsp;Maxime Guéguinou ,&nbsp;Olivier Herault ,&nbsp;Aurélie Ferru ,&nbsp;Cédric Pobel ,&nbsp;Olivier Sire ,&nbsp;Thierry Lecomte","doi":"10.1016/j.dld.2024.07.022","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><div>Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment. We aimed to evaluate the prognostic yield of serum mid-infrared spectroscopy (MIRS) on patients receiving first-line bevacizumab-based chemotherapy for mCRC.</div></div><div><h3>Methods</h3><div>We conducted an ancillary analysis from a multicentre prospective study (NCT00489697). All baseline serums were screened by attenuated total reflection method. Principal component analysis and unsupervised k-mean partitioning methods were performed blinded to all patients’ data. Endpoints were progression-free survival (PFS) and overall survival (OS).</div></div><div><h3>Results</h3><div>From the 108 included patients, MIRS discriminated two prognostic groups. First group patients had significantly lower body mass index (<em>p</em> = 0.026) and albumin levels (<em>p</em> &lt; 0.001), and higher levels of angiogenic markers, lactate dehydrogenase and carcinoembryonic antigen (<em>p</em> &lt; 0.001). In univariate analysis, their OS and PFS were shorter with respective medians: 17.6 vs 27.9 months (<em>p</em> = 0.02) and 8.7 vs 11.3 months (<em>p</em> = 0.03). In multivariate analysis, PFS was significantly shorter (HR = 1.74, <em>p</em> = 0.025) with a similar trend for OS (HR = 1.69, <em>p</em> = 0.061).</div></div><div><h3>Conclusion</h3><div>By metabolomic fingerprinting, MIRS proves to be a promising prognostic tool for patients receiving first-line bevacizumab-based chemotherapy for mCRC.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 1","pages":"Pages 141-148"},"PeriodicalIF":4.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestive and Liver Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1590865824008867","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims

Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment. We aimed to evaluate the prognostic yield of serum mid-infrared spectroscopy (MIRS) on patients receiving first-line bevacizumab-based chemotherapy for mCRC.

Methods

We conducted an ancillary analysis from a multicentre prospective study (NCT00489697). All baseline serums were screened by attenuated total reflection method. Principal component analysis and unsupervised k-mean partitioning methods were performed blinded to all patients’ data. Endpoints were progression-free survival (PFS) and overall survival (OS).

Results

From the 108 included patients, MIRS discriminated two prognostic groups. First group patients had significantly lower body mass index (p = 0.026) and albumin levels (p < 0.001), and higher levels of angiogenic markers, lactate dehydrogenase and carcinoembryonic antigen (p < 0.001). In univariate analysis, their OS and PFS were shorter with respective medians: 17.6 vs 27.9 months (p = 0.02) and 8.7 vs 11.3 months (p = 0.03). In multivariate analysis, PFS was significantly shorter (HR = 1.74, p = 0.025) with a similar trend for OS (HR = 1.69, p = 0.061).

Conclusion

By metabolomic fingerprinting, MIRS proves to be a promising prognostic tool for patients receiving first-line bevacizumab-based chemotherapy for mCRC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估血清中红外光谱作为转移性结直肠癌一线贝伐珠单抗化疗的新预后指标。
背景和目的:以贝伐单抗为基础的化疗是转移性结直肠癌(mCRC)的推荐一线治疗方法。目前尚未发现适用于接受这种治疗的患者的临床实践的可靠生物标志物。我们旨在评估血清中红外光谱(MIRS)对接受贝伐珠单抗一线化疗的 mCRC 患者的预后影响:我们对一项多中心前瞻性研究(NCT00489697)进行了辅助分析。所有基线血清均采用减弱全反射法进行筛选。在对所有患者数据保密的情况下,进行了主成分分析和无监督k均值分割方法。终点为无进展生存期(PFS)和总生存期(OS):结果:在108名纳入的患者中,MIRS可区分出两个预后组。第一组患者的体重指数(P = 0.026)和白蛋白水平(P < 0.001)明显较低,血管生成标志物、乳酸脱氢酶和癌胚抗原水平较高(P < 0.001)。在单变量分析中,他们的 OS 和 PFS 较短,中位数分别为 17.6 个月 vs 27.9 个月:中位数分别为:17.6 个月 vs 27.9 个月(P = 0.02)和 8.7 个月 vs 11.3 个月(P = 0.03)。在多变量分析中,PFS 明显缩短(HR = 1.74,p = 0.025),OS 也有类似趋势(HR = 1.69,p = 0.061):通过代谢组指纹图谱,MIRS被证明是一种很有前途的预后工具,适用于接受贝伐珠单抗一线化疗的mCRC患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Digestive and Liver Disease
Digestive and Liver Disease 医学-胃肠肝病学
CiteScore
6.10
自引率
2.20%
发文量
632
审稿时长
19 days
期刊介绍: Digestive and Liver Disease is an international journal of Gastroenterology and Hepatology. It is the official journal of Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Pancreas (AISP); Italian Association for Digestive Endoscopy (SIED); Italian Association for Hospital Gastroenterologists and Digestive Endoscopists (AIGO); Italian Society of Gastroenterology (SIGE); Italian Society of Pediatric Gastroenterology and Hepatology (SIGENP) and Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease publishes papers on basic and clinical research in the field of gastroenterology and hepatology. Contributions consist of: Original Papers Correspondence to the Editor Editorials, Reviews and Special Articles Progress Reports Image of the Month Congress Proceedings Symposia and Mini-symposia.
期刊最新文献
Global burden of gallbladder cancer in 2022 and predictions to 2042. Author's reply: "Navigating anti-TNF therapy risks: Real-world insights on pregnancy, breastfeeding, and vaccines in IBD patients". Endoscopic healing in IBD: Still the target to achieve? Pancreatic fat density and post-ERCP pancreatitis: A complex relationship or a novel predictor? A two-transcript classifier model for assessing disease activity in patients with ulcerative colitis: A discovery and validation study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1